GlassScriptPhysician profile
Kurt A Buechler
NPI 1922146760
$1,106,970.58
in general payments reported to CMS, 2019-2025
26 companies · $322K in 2025
The $322K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $62K · 2021: $101K · 2022: $139K · 2023: $225K · 2024: $160K · 2025: $322K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $410K · Honoraria: $109K · Travel and Lodging: $104K · Consulting Fee: $64K · Food and Beverage: $20K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $410,044.99 |
| Honoraria | $108,600.00 |
| Travel and Lodging | $103,564.70 |
| Consulting Fee | $64,350.00 |
| Food and Beverage | $20,420.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483,710.68 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $213,996.16 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $212,268.02 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $66,653.69 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $57,825.95 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $38,824.78 | 2019-2025 | Trintellix |
| Eisai INC. | $26,513.93 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $3,688.26 | 2019-2023 | Spravato |
| Tris Pharma INC | $707.87 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $612.32 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $358.94 | 2021-2024 | Caplyta |
| Ironshore Pharmaceuticals INC. | $326.56 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $297.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $226.35 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $165.13 | 2019-2023 | Belsomra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $150.87 | 2019-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $133.28 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $133.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $130.73 | 2022-2024 | Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $94.96 | 2021-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.66 | 2022-2025 | |
| Corium, LLC | $28.69 | 2025 | Azstarys |
| Arbor Pharmaceuticals, INC. | $26.41 | 2019 | |
| Harmony Biosciences LLC | $20.47 | 2023 | Wakix |
| Idorsia Pharmaceuticals US INC | $13.93 | 2024 | Quviviq |
| Janssen Scientific Affairs, LLC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Buechler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.